KR840007568A - Method for preparing substituted dipeptides - Google Patents

Method for preparing substituted dipeptides Download PDF

Info

Publication number
KR840007568A
KR840007568A KR1019830005539A KR830005539A KR840007568A KR 840007568 A KR840007568 A KR 840007568A KR 1019830005539 A KR1019830005539 A KR 1019830005539A KR 830005539 A KR830005539 A KR 830005539A KR 840007568 A KR840007568 A KR 840007568A
Authority
KR
South Korea
Prior art keywords
phenyl
phenylethyl
alanine
carbonyl
phenylalanyl
Prior art date
Application number
KR1019830005539A
Other languages
Korean (ko)
Other versions
KR910002549B1 (en
Inventor
길버트 버거 조엘
Original Assignee
스타이나 칸스 테드, 로즈마리 아이젠링
쉐링 코포레이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타이나 칸스 테드, 로즈마리 아이젠링, 쉐링 코포레이숀 filed Critical 스타이나 칸스 테드, 로즈마리 아이젠링
Publication of KR840007568A publication Critical patent/KR840007568A/en
Application granted granted Critical
Publication of KR910002549B1 publication Critical patent/KR910002549B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/373Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in doubly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/84Unsaturated compounds containing keto groups containing six membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/89Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.No content.

Description

치환된 디펩티드의 제조방법Method for preparing substituted dipeptides

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (9)

a) 하기 일반식(XX)의 화합물의 C=N 이중결합을 환원시키거나a) reducing the C = N double bond of the compound of formula (XX) b) 하기 일반식(II)의 케토산이나 에스테트를 환원제를 함유한 반응성 매질내에서 하기 일반식(III)의 화합물과 축합시키거나,b) condensing a keto acid or ester of formula (II) with a compound of formula (III) in a reactive medium containing a reducing agent, or c) 하기 일반식(VIII)의 아미노산을 하기 일반식(V)의 아미노산과 결합(coupling)시키거나c) combining the amino acid of the general formula (VIII) with the amino acid of the general formula (V) d) 하기 일반식(XXi)의 화합물의 C=N 이중결합을 환원시키거나d) reducing the C = N double bond of the compound of formula (XXi) e) 하기 일반식(X)의 케토산이나 에스테르를 환원제를 함유한 반응성 매질내에서 하기 일반식(XXIII)의 아미노산과 축합시키거나e) condensing the keto acid or ester of formula (X) with an amino acid of formula (XXIII) in a reactive medium containing a reducing agent, or f) 하기 일반식(III)의 화합물을 하기 일반식(XXII)의 화합물과 알킬화 시킨후, 보호그룹을 제거하고 필요에 따라, 상기 반응에 의해 형성된 화합물을 상기에서 정의한 바와 같은 다른 일반식(I)의 화합물로 전환시키고/시키거나 이들의 염을 형성시킨후, 필요에 따라 목적한 이성체를 분리함을 특징으로 하여 하기 일반식(I)의 화합물 또는 이를 함유한 에난티오머 또는 디아스테레오 아이소머혼합물 및 이의 약리학적으로 허용되는 염을 제조하는 방법.f) after alkylating a compound of the general formula (III) with a compound of the general formula (XXII), removing the protecting group and, if necessary, the compound formed by the above reaction with another general formula (I) as defined above. A compound of formula (I) or an enantiomer or diastereo isomer containing the same, characterized in that the desired isomer is isolated after conversion to a compound of A process for preparing the mixture and its pharmacologically acceptable salts. 상기 일반식에서, R1은 탄소수 1내지 6, 알킬, 아다맨틸메틸, 탄소수 4 내지 8의 시클로알킬메틸 또는 A-Xm-CnH2n-[여기서 X는 산소 또는 황이고, A는 그룹 Y로 치환될 수 있는 페닐(여기서 Y, 할로겐히드록시, 프리플루오로메틸, 탄소수 1 내지 6의 알콕시, 탄소수 1 내지 6의 알킬, 2- 또는 3-푸라닐, 2- 또는 3-티에닐 또는 페닐(이 페닐은 할로겐, 히드록시, 트리플루오로메틸, 탄소수 1 내지 6의 알콕시 또는 탄소수 1 내지 6의 알킬로 치환될 수 있다)이다], 벤질(이것의 페닐환은 상기에서 정의한 그룹 Y로 치환될 수 있다), 1- 또는 2-나프틸, 2- 또는 3-푸라닐, 또는 2- 또는 3-티에닐이며, m은 0 또는 1이고, n은 1, 2, 3 또는 4이다]이고, R2와 R6는 서로 동일하거나 다를 수 있으며 히드록시, 탄소수 1 내지 8의 알콕시, B-Xm-CnH2n-O-(여기서 B는(상기에서 정의한 그룹 Y로 치환될 수 있는 페닐, 또는 1-이나 2-나프틸이고, X, m 및 n은 상기에서 정의한 바와 같으며, 단, n=0일 때 m 또한 0이다), -OCH2OCO-알킬(여기서 알킬은 탄소수 1 내지 6의 알킬이다), -OCH2CO-페닐(여기서 페닐환은 상기에서 정의한 바와같은 그룹 Y로 치환될 수 있다), 1-글리세릴,또는(여기서 R7은 수소, 탄소수 1 내지 6의 알킬 또는 상기에서 정의한 바와 같은 그룹 Y로 치환될 수 있는 페닐이고, R8은 수소 또는 탄소수 1 내지 6의 알킬이다), R2는 또한 -NR6R8(여기서 R7및 R8은 상기에서 정의한 바와 같다)일 수 있고, R3는 탄소수 1 내지 6의 알킬, 탄소수 4내지 8의 시클로알킬메틸, 2- 또는 3-티에닐메틸, 2- 또는 3-푸라닐메틸, 1- 또는 2-나프틸메틸 또는 벤질(이것의 페닐환은 상기에서 정의한 그룹 Y로 치환될 수 있다)이고, R4는 D-CnH2n-Om-[여기서 D는 수소, 탄소수 1 내지 4의 알킬 또는 그룹 Z(이 Z는 할로겐, 히드록시, 트리플루오로메틸, 탄소수 1 내지 6의 알콕시 또는 탄소수 1 내지 6의 알킬이다)로 치환될 수 있는 페닐이고 m과 n은 상기에서 정의한 바와 같다]이고, R5는 수소 또는 탄소수 1 내지 6의 알킬이고, p는 0, 1 또는 2이며, 일반식(XXII)에서의 X는 할로겐이고, 반응물중의 반응성그룹은 보호시키며, 단, R1이 탄소수 1 내지 6의 알킬, 탄소수 4 내지 8의 시클로알킬메틸 또는 A-Xm-CnH2n-[여기서(i) A는 페닐 그룹이나 벤질 그룹중의 페닐잔기가 그룹 Y′(이 Y′는 할로겐, 히드록시, 트리플루오로메틸, 탄소수 1 내지 6의 알콕시 또는 탄소수 1 내지 6의 알킬이다)에 의해 임의로 치환된 페닐 또는 벤질인 경우를 제외하고는 상기에서 정의한 바와같고, n은 또. 1 내지 4이고 m은 0 또는 1이며, X는 산소이거나, (ii) A는 상기에서 정의한 그룹 Y′에 의해 임의로 치환된 페닐 또는 벤질이고 n은 1 내지 4이고 m은 1이며 X는 황이다]이고, R3가 탄소수 1 내지 6의 알킬, 탄소수 4 내지 8의 시클로알킬메틸, 2- 또는 3-티에닐메틸, 2- 또는 3-푸라닐메틸, 1- 또는 2-나프틸메틸, 또는 벤질(이것의 페닐환은 상기에서 정의한 그룹 Y′에 의해 치환될 수 있다)이고, R4가 D-CnH2n-Om-[여기서 (i) D는 수소, 탄소수 1 내지 4의 알킬 또는 상기에서 정의한 그룹 Y′에 의해 치환될 수 있는 페닐이고, m은 0이며 n은 1 내지 4이거나, (ii) D는 수소 또는 그룹 Y′에 의해 임의로 치환된 페닐이고 m과 n은 모두 0이다]이며, R5및 p가 상기에서 정의한 바와 같을 경우, R2와 R6중 적어도 하나는 B-Xm-CnX2n-O-[여기서 (i) B와 X가 상기에서 정의한 바와 같고 m은 1이며 n은 1 내지 4이거나, (ii) B는 1- 또는 3-푸라닐, 2- 또는 3-티에닐 또는 페닐(이것은 할로겐, 히드록시, 트리플루오로메틸, 탄소수 1 내지 6의 알콕시 또는 탄소수 1 내지 6의 알킬에 의해 치환될 수 있다)로 치환된 페닐이고 m은 0이며(은 또는 1 내지 4이다), 피발로일옥시메틸,(이 페닐그룹은 상기에서 정의한 그룹 Y에 의해 치환될 수 있다), 1-글리세릴,(여기서 R7및 R8은 상기에서 정의한 바와 같다)중에서 선택한 것이어야 하거나, R2는 -NR7R8(여기서 R7은 상기에서 정의한 Y′에 의해 치환된 페닐이고, R8은 상기에서 정의한 바와 같다)중에서 선택한 것이어야 하며,Said general formula, R 1 is C 1 -C 6, alkyl, Ada maentil methyl, cycloalkyl having 4 to 8 carbon atoms or methyl AX m -C n H 2n -, and - wherein X is oxygen or sulfur, A is substituted with a group Y Phenyl which may be selected from Y, halogenhydroxy, prefluoromethyl, alkoxy having 1 to 6 carbon atoms, alkyl having 1 to 6 carbon atoms, 2- or 3-furanyl, 2- or 3-thienyl or phenyl Phenyl may be substituted with halogen, hydroxy, trifluoromethyl, alkoxy having 1 to 6 carbon atoms or alkyl having 1 to 6 carbon atoms], benzyl (its phenyl ring may be substituted with group Y as defined above) ), 1- or 2-naphthyl, 2- or 3-furanyl, or 2- or 3-thienyl, m is 0 or 1, n is 1, 2, 3 or 4], and R 2 And R 6 may be the same or different from each other and may be selected from the group consisting of hydroxy, alkoxy having 1 to 8 carbon atoms, BX m -C n H 2n -O- (where B Phenyl which may be substituted, or 1- or 2-naphthyl, X, m and n are as defined above, provided that m is also 0 when n = 0, -OCH 2 OCO-alkyl, wherein Alkyl is alkyl having 1 to 6 carbon atoms, -OCH 2 CO-phenyl, wherein the phenyl ring may be substituted by group Y as defined above, 1-glyceryl, or Wherein R 7 is hydrogen, alkyl of 1 to 6 carbon atoms or phenyl which may be substituted by group Y as defined above and R 8 is hydrogen or alkyl of 1 to 6 carbon atoms, R 2 is also -NR 6 R 8 (where R 7 and R 8 are as defined above), R 3 is alkyl having 1 to 6 carbons, cycloalkylmethyl having 4 to 8 carbons, 2- or 3-thienylmethyl, 2- Or 3-furanylmethyl, 1- or 2-naphthylmethyl or benzyl, whose phenyl ring may be substituted by group Y as defined above, where R 4 is DC n H 2n -O m-, where D is Phenyl which may be substituted by hydrogen, alkyl of 1 to 4 carbon atoms or group Z (wherein Z is halogen, hydroxy, trifluoromethyl, alkoxy of 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms) and m and n Is as defined above, R 5 is hydrogen or alkyl of 1 to 6 carbon atoms, p is 0, 1 or 2, X in formula (XXII) is halogen, and the reactive group in the reactant is protected, provided that R 1 is alkyl of 1 to 6 carbon atoms, cycloalkylmethyl of 4 to 8 carbon atoms or AX m -C n H 2n- [Wherein (i) A is a phenyl residue in a phenyl group or a benzyl group is a group Y '(this Y' is halogen, hydroxy, trifluoromethyl, alkoxy having 1 to 6 carbon atoms or alkyl having 1 to 6 carbon atoms) Is as defined above except for phenyl or benzyl, optionally substituted by 1 to 4 and m is 0 or 1 and X is oxygen or (ii) A is phenyl or benzyl optionally substituted by group Y 'as defined above, n is 1 to 4 and m is 1 and X is sulfur ] And R 3 is alkyl having 1 to 6 carbon atoms, cycloalkylmethyl having 4 to 8 carbon atoms, 2- or 3-thienylmethyl, 2- or 3-furanylmethyl, 1- or 2-naphthylmethyl, or Benzyl (its phenyl ring may be substituted by group Y 'as defined above) and R 4 is DC n H 2n -O m- [wherein (i) D is hydrogen, alkyl of 1 to 4 carbon atoms or Phenyl which may be substituted by defined group Y ', m is 0 and n is 1-4, or (ii) D is hydrogen or phenyl optionally substituted by group Y' and m and n are both 0] , R 5 and p are the same as defined in the case, at least one of R 2 and R 6 are the same as the BX m -C n X 2n -O- [wherein (i) B and X as defined above m is 1 and n is 1 to 4, or (ii) B is 1- or 3-furanyl, 2- or 3-thienyl or phenyl (which is halogen, hydroxy, trifluoromethyl, of 1 to 6 carbon atoms) Phenyl substituted with alkoxy or alkyl having 1 to 6 carbon atoms, m is 0 (silver or 1 to 4), pivaloyloxymethyl, (This phenyl group may be substituted by group Y as defined above), 1-glyceryl, And Wherein R 7 and R 8 are as defined above, or R 2 is —NR 7 R 8 where R 7 is phenyl substituted by Y ′ as defined above and R 8 is As defined), 제1항에 있어서, R4가 그룹 D-CnH2n-Om-[여기서 D는 수소, 탄소수 1 내지 4의 알킬 또는 그룹 Z(이 Z는 할로겐, 히드록시, 트리플루오로메틸, 탄소수 1 내지 6의 알콕시 또는 탄소수 1 내지 6의 알킬이다)로 치환될 수 있는 페닐이고, m은 0 또는 1이고 n은 0, 1, 2, 3 또는 4이며, 단, n+m≥1)인 일반식(I)의 화합물을 제조함을 특징으로 하는 방법.The compound of claim 1, wherein R 4 is a group DC n H 2n -O m -wherein D is hydrogen, alkyl of 1 to 4 carbon atoms or group Z, wherein Z is halogen, hydroxy, trifluoromethyl, 1 to C Alkoxy of 6 or alkyl of 1 to 6 carbon atoms), m is 0 or 1 and n is 0, 1, 2, 3 or 4, provided that n + m ≧ 1) A process characterized by preparing the compound of (I). 제1항 또는 제2항에 있어서, R2및 R8중 어느 하나는2-페녹시에톡시, 1-글리세릴,,, 또는 (2,2-디메닐-1-옥소프로폭시)메톡시이고, 그 나머지는 제1항에서 정의한 그룹중에서 선택하거나 히드록시, 메톡시, 에톡시 또는 벤질옥시인 일반식(I)의 화합물을 제조함을 특징으로 하는 방법.The compound of claim 1 or 2, wherein any one of R 2 and R 8 is 2-phenoxyethoxy, 1-glyceryl, , Or (2,2-dimenyl-1-oxopropoxy) methoxy, the remainder of which is selected from the group defined in claim 1 or is hydroxy, methoxy, ethoxy or benzyloxy Process for the preparation of a compound. 제1항 또는 제2항에 있어서, R1이 염소, 메톡시, 메틸, 또는 페닐에 의해 임의로 파라 치환된 벤질, 2-페닐에틸 또는 1-이나 2-나프닐메틸이고, R2및 R6는 서로 동일하거나 다르며, 히드록시, 메톡시, 에톡시, 벤질옥시, 2-페닐녹시에톡시, 1-글리세릴,3. The compound of claim 1, wherein R 1 is benzyl, 2-phenylethyl or 1- or 2-naphthylmethyl optionally para substituted by chlorine, methoxy, methyl, or phenyl, and R 2 and R 6. Are the same or different from each other, and are hydroxy, methoxy, ethoxy, benzyloxy, 2-phenyloxyethoxy, 1-glyceryl, ,, 또는 (2-2-디메틸-1-옥소프로폭시)메톡시이고, R3는 벤질, p-메틸벤질, p-페닐벤질, 1-나프틸메틸 또는 3-티에닐메틸인 화합물을 제조함을 특징으로 하는 방법. , , Or (2-2-dimethyl-1-oxopropoxy) methoxy and R 3 is benzyl, p-methylbenzyl, p-phenylbenzyl, 1-naphthylmethyl or 3-thienylmethyl Characterized by the above. 제4항에 있어서, R4가 메틸 또는 벤질이고, R5가 수소인 화합물을 제조함을 특징으로 하는 방법.5. A process according to claim 4, wherein R 4 is methyl or benzyl and R 5 is hydrogen. 제3항에 있어서, R1및 R3가 제4항에서 정의한 바와 같고, R3가 수소, 메틸 또는 벤질이고, R5가 수소인 화합물을 제조함을 특징으로 하는 방법.4. A process according to claim 3, wherein R 1 and R 3 are as defined in claim 4, wherein R 3 is hydrogen, methyl or benzyl and R 5 is hydrogen. 제6항에 있어서, R4가 수소임을 특징으로 하는 방법.The method of claim 6, wherein R 4 is hydrogen. 제1 내지 7항중 어느 한항에 있어서, p가 1인 화합물을 제조함을 특징으로 하는 방법.8. Process according to any one of the preceding claims, characterized in that a compound is prepared wherein p is 1. 제1항에 있어서, 하기 화합물 또는 약리학적으로 허용되는 염을 제조함을 특징으로 하는 방법. N-[N-[L-1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L-페닐알라닐]-β-알라닌, (2,2-디메틸-1-옥소프로폭시)메틸 에스테르, N-[N-[L-[1-[페닐메톡시]카보닐]-2-페닐메틸]-L-페닐알라닐]-β-알라닌, (2,2-디메닐-1-옥소프로폭시)메틸 에스테르, N-[N-[L-1-카복시-2-(4-페닐)페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1옥소프로폭시) 메톡시]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-β-알라닌, (2,2 -디메틸-1-옥소프로폭시)메틸 에스테르, N-[N-[L-1-카복시-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐-β-알라닌, (2,2-디메탈-1-옥소프로폭시)메틸 에스테르; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌, (2,2-디메틸-1-옥소프로폭시)메틸 에스테르; N-[L-1-카복시-2-페닐에틸]-1-페닐알라닐-β-알라닌, 2,2-디메틸-1,3-디옥솔란-4-일-메틸 에스테르, 융점 153 내지 158℃; N-[N-[L-[1-(2,2-디메틸-1,3-디옥솔린-4-일)메톡시]-카보닐]-2-페닐에틸]-L-페닐알라닐, 말레이트 염; N-[N-[L-1-카복시-2-페닐에틸]-L-페닐알라닐]-L-(α-메틸)-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-L-페닐알라닐]-L-(α-메틸)-β알라닌, (2,2-디메틸-1-옥소프로폭시)메틸, 에스테르; -N-[N-[(L-1-카복시-2-페닐에틸)]-L-페닐알라닐]-β-알라닌, 2-페녹시에틸, 에스테르; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐]-2-페닐에틸]-L-페닐알라닐-β-알라닌 N-[N-[L-[1-[(1-옥소-3-이소벤조 푸라닐옥시)카보닐]-2-페닐에틸]-L-페닐알라닐]-β-알라닌 N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N-[1-[(2,2-디메틸-1,3-디옥솔린-4-일)메톡시]-카보닐]-2-페닐에틸]-L-페닐 알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]2-(4-페닐)페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N- [L- [1- [(2-페녹시)에톡시]카보닐]-2-(4-페닐)-페닐에틸]-L-페닐알라닐-β-알라닌; N-[N-[L-[1-[(1-옥소-3-이소벤조푸라닐옥시)]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닌]-β-알라닌; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1,3-디옥솔란-4-일]-2-(4-메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N- [N-[L-[1-[(1-옥소-3-이소벤조푸라닐옥시)]카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닐; N-[N-[L-[1-[(2,3-디히드록시-1프로폭시]카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸)-1,3-디옥솔란-4-일)메톡시]-카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐]-2-(4-페닐)-페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1- [(1-옥소-3-이소벤조푸라닐옥시)]카보닐]-2-(4-페닐)페닐에틸-L-(4-페닐)페닐알라닐]-β-알라닐; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-1[2,2-디메틸-1,3-디옥솔란-4-일)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-2-카보닐]-2-페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐] -2-페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(1-옥소-3-이소벤조푸라닐옥시)]카보닐]-2-페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1,3-디옥솔란-4-일)메톡시]-카보닐]-2-페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-E,L-α-메틸-β-알라닌; N-[N-[L-[1-[(1-옥소-3-이소벤조푸라닐옥시)]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-(4-페닐)페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌: N-[N-[L-[1-[(2,2-디메틸-1,3-디옥솔란-4-일)메톡시]-2-(4-카보닐]-2-페닐)페닐에틸]-L-페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-메틸-α-알라닌; N-[N-[L-[1-[2-페녹시)에톡시]카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L- [1-[(1-옥소-3-이소벤조푸라닐옥시)] 카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닌]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[ (2,2- 디메틸- 1,3-디옥솔란-4-일)메톡시-카보닐]-2-페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-페닐-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2-페녹시)에톡시]카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N- [L-[1-옥소-3-이소벤조푸라닐옥시) ]카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,3-디히드록시)-1-프로폭시]카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1,3-디옥솔란-4-일)메톡시]-카보닐]-2-(4-페닐)페닐에틸]-L-(4-페닐)페닐알라닐]-D,L-α-메틸-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]-카보닐]-2-페닐에틸]-2-티에닐알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L-3-티에틸알라닐]-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸-L-2-푸로알라닐]-β-알라닌; N-[N-[L-[1-[1-(2,2- 디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸] -L-페닐알라닐]-α- 메틸알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L-페닐알라닐]α-메틸알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시]메톡시]카보닐]-2-페닐에틸]-L-페닐알라닐]-L-α-히드록시-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L -페닐알라닐]-D-α-히드록시-β-알라닌; N-[N-[L-[1-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에닐]-L-페닐알라닐]-L-α-메폭시-β-알라닌; N -[N-[L-[1-[(2,2-디메틸 -1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L-페닐알라닐]-D-α-메톡시-β-알라닌; N-[N-[L-[I-[(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-페닐에틸]-L-페닐알라닐-D,L-α-메틸-β-알라닌 벤질 에스테르; N-[N-[N-[L-[1-(2,2-디메틸-1-옥소프로폭시)메톡시]카보닐]-2-(4-메톡시)페닐에틸]-L-페닐알라닐-β-알라닌; N-[(L)-1-카복시-2-페닐에틸]-L-페닐 알라닐-L-페닐알라닌; N-[(L)-1-카복시-2-페닐에틸]-L-루이실-L-페닐알라닌;The method of claim 1, wherein the following compound or pharmacologically acceptable salt is prepared. N- [N- [L-1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -β-alanine, (2 , 2-dimethyl-1-oxopropoxy) methyl ester, N- [N- [L- [1- [phenylmethoxy] carbonyl] -2-phenylmethyl] -L-phenylalanyl] -β-alanine , (2,2-dimenyl-1-oxopropoxy) methyl ester, N- [N- [L-1-carboxy-2- (4-phenyl) phenylethyl] -L-phenylalanyl] -β- Alanine; N- [N- [L- [1-[(2,2-dimethyl-1oxopropoxy) methoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -β -Alanine, (2,2-dimethyl-1-oxopropoxy) methyl ester, N- [N- [L-1-carboxy-2-phenylethyl] -L- (4-phenyl) phenylalanyl] -β Alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl ) Phenylalanyl-β-alanine, (2,2-dimetal-1-oxopropoxy) methyl ester; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine, (2,2-dimethyl-1-oxopropoxy) methyl ester; N- [L-1-carboxy-2-phenylethyl] -1-phenylalanyl-β-alanine, 2,2-dimethyl-1,3-dioxolan-4-yl-methyl ester, melting point 153 to 158 ° C ; N- [N- [L- [1- (2,2-dimethyl-1,3-dioxolin-4-yl) methoxy] -carbonyl] -2-phenylethyl] -L-phenylalanyl, Rate salts; N- [N- [L-1-carboxy-2-phenylethyl] -L-phenylalanyl] -L- (α-methyl) -β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2-phenylethyl] -L-phenylalanyl] -L- (α -Methyl) -β alanine, (2,2-dimethyl-1-oxopropoxy) methyl, ester; -N- [N-[(L-1-carboxy-2-phenylethyl)]-L-phenylalanyl] -β-alanine, 2-phenoxyethyl, ester; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2-phenylethyl] -L-phenylalanyl] -β-alanine; N- [N- [L- [1-[(2-phenoxy) ethoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl-β-alanine N- [N- [L- [1 -[(1-oxo-3-isobenzofuranyloxy) carbonyl] -2-phenylethyl] -L-phenylalanyl] -β-alanine N- [N- [L- [1-[(2, 3-dihydroxy) -1-propoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -β-alanine; N- [N- [1-[(2,2-dimethyl-1,3-dioxolin-4-yl) methoxy] -carbonyl] -2-phenylethyl] -L-phenyl alanyl] -β- Alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] 2- (4-phenyl) phenylethyl] -L-phenylalanyl]- β-alanine; N- [N- [L- [1-[(2-phenoxy) ethoxy] carbonyl] -2- (4-phenyl) -phenylethyl] -L-phenylalanyl-β-alanine; N- [N- [L- [1-[(1-oxo-3-isobenzofuranyloxy)] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanine] -β-alanine; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -β Alanine; N- [N- [L- [1-[(2,2-dimethyl-1,3-dioxolan-4-yl] -2- (4-methoxy] -carbonyl] -2- (4-phenyl ) Phenylethyl] -L-phenylalanyl] -β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2 -Phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(2-phenoxy) ethoxy] carbonyl] -2-phenylethyl ] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(1-oxo-3-isobenzofuranyloxy)] carbonyl] -2- Phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanyl; N- [N- [L- [1-[(2,3-dihydroxy-1 propoxy] carbonyl]- 2-phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(2,2-dimethyl) -1,3-dioxolane-4 -Yl) methoxy] -carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(2,2- Dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L -[1-[(2-phenoxy) ethoxy] carbonyl] -2- (4-phenyl) -phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(1-oxo-3-isobenzofuranyloxy)] carbonyl] -2- (4-phenyl) phenylethyl-L- (4-phenyl) phenylalanyl ] -β-alanyl; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L -(4-phenyl) phenylalanyl] -β-alanine; N- [N- [L-1 [2,2-dimethyl-1,3-dioxolan-4-yl) methoxy] -carbonyl]- 2- (4-phenyl) phenylethyl] -L- (4-phenyl) phenylalanyl] -β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopro) Foxy) methoxy] -2-carbonyl] -2-phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[( 2-phenoxy) ethoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[( 1-oxo-3-isobenzofuranyloxy)] carbonyl] -2-phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1,3-dioxolan-4-yl) methoxy] -carbonyl] -2-phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2-phenoxy) ethoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -E, L-α-methyl -β-alanine; N- [N- [L- [1-[(1-oxo-3-isobenzofuranyloxy)] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L-phenylalanyl] -D , L-α-methyl-β-alanine: N- [N- [L- [1-[(2,2-dimethyl-1,3-dioxolan-4-yl) methoxy] -2- (4- Carbonyl] -2-phenyl) phenylethyl] -L-phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanyl] -D, L-methyl-α-alanine; N- [N- [L- [1- [2-phenoxy) ethoxy] carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanyl] -D, L-α-methyl- β-alanine; N- [N- [L- [1-[(1-oxo-3-isobenzofuranyloxy)] carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanine] -D, L- α-methyl-β-alanine; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2-phenylethyl] -L- (4-phenyl) phenylalanyl] -D , L-α-methyl-β-alanine; N- [N- [L- [1- [(2,2-Dimethyl-1,3-dioxolan-4-yl) methoxy-carbonyl] -2-phenylethyl] -L- (4-phenyl) Phenylalanyl] -D, L-α-phenyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl ) Phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2-phenoxy) ethoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl) phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-oxo-3-isobenzofuranyloxy)] carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl) phenylalanyl-D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,3-dihydroxy) -1-propoxy] carbonyl] -2- (4-phenyl) phenylethyl] -L- (4-phenyl) phenyl Alanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1,3-dioxolan-4-yl) methoxy] -carbonyl] -2- (4-phenyl) phenylethyl] -L -(4-phenyl) phenylalanyl] -D, L-α-methyl-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] -carbonyl] -2-phenylethyl] -2-thienylalanyl] -β-alanine ; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl] -L-3-thiethylalanyl] -β- Alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl-L-2-furoalanyl] -β-alanine; N- [N- [L- [1- [1- (2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -α-methyl Alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] α-methylalanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy] methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -L-α-hydrate Roxy-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl] -D-α-hydroxy-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2-phenylenyl] -L-phenylalanyl] -L-α-mepoxy-β-alanine; N- [N- [L- [1-[(2,2-dimethyl-1-oxopropoxy) methoxy] carbonyl] 2-phenylethyl] -L-phenylalanyl] -D-α-methoxy-β-alanine; N- [N- [L- [I-[(2,2-dimethyl-1-oxopropoxy) Methoxy] carbonyl] -2-phenylethyl] -L-phenylalanyl-D, L-α-methyl-β-alanine benzyl ester; N- [N- [N- [L- [1- (2, 2-dimethyl-1-oxopropoxy) methoxy] carbonyl] -2- (4-methoxy) phenylethyl] -L-phenylalanyl-β-alanine; N-[(L) -1-carboxy- 2-phenylethyl] -L-phenylalanyl-L-phenylalanine N-[(L) -1-carboxy-2-phenylethyl] -L-leusil-L-phenylalanine; ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019830005539A 1982-11-26 1983-11-23 Substituted dipeptides method for their production KR910002549B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44476182A 1982-11-26 1982-11-26
US444,761 1982-11-26
US444761 1982-11-26
US48346383A 1983-04-11 1983-04-11
US483,463 1983-04-11

Publications (2)

Publication Number Publication Date
KR840007568A true KR840007568A (en) 1984-12-08
KR910002549B1 KR910002549B1 (en) 1991-04-24

Family

ID=27034046

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830005539A KR910002549B1 (en) 1982-11-26 1983-11-23 Substituted dipeptides method for their production

Country Status (11)

Country Link
KR (1) KR910002549B1 (en)
AU (1) AU565481B2 (en)
CA (1) CA1250091A (en)
DK (1) DK533483A (en)
FI (1) FI78917C (en)
HU (1) HU193887B (en)
IL (1) IL70309A (en)
NO (1) NO169172C (en)
NZ (1) NZ206362A (en)
OA (1) OA07594A (en)
PT (1) PT77699B (en)

Also Published As

Publication number Publication date
NO834294L (en) 1984-05-28
AU2157783A (en) 1984-05-31
KR910002549B1 (en) 1991-04-24
FI834280A0 (en) 1983-11-23
DK533483A (en) 1984-05-27
IL70309A (en) 1988-11-30
NO169172B (en) 1992-02-10
NZ206362A (en) 1988-11-29
AU565481B2 (en) 1987-09-17
CA1250091A (en) 1989-02-14
PT77699A (en) 1983-12-01
OA07594A (en) 1985-03-31
PT77699B (en) 1986-05-12
HU193887B (en) 1987-12-28
FI834280A (en) 1984-05-27
IL70309A0 (en) 1984-02-29
DK533483D0 (en) 1983-11-22
FI78917B (en) 1989-06-30
NO169172C (en) 1992-05-27
FI78917C (en) 1989-10-10

Similar Documents

Publication Publication Date Title
AU602547B2 (en) Aryloxy and arylacyloxy methyl ketones thiol protease inhibitors
KR920021578A (en) Phosphno / biaryl substituted dipeptide derivatives
Shi et al. Visualizing the replication cycle of bunyamwera orthobunyavirus expressing fluorescent protein-tagged Gc glycoprotein
KR940006177A (en) Discharge reactor
KR850004273A (en) Recombinant gamma interferon with increased stability and preparation method thereof
KR890008072A (en) Benzocycloheptene derivatives
CO5090908A1 (en) PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES
RU97114956A (en) METHOD OF INHIBITING INTER CELL ADHESION AND METHOD OF INHIBITING THE INFLAMMATORY PROCESS
US4906615A (en) Substituted dipeptides as inhibitors of enkephalinases
US5158936A (en) Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
KR840007568A (en) Method for preparing substituted dipeptides
KR950700234A (en) Method for preparing β-phenylisoserine and analogues thereof
KR850001774A (en) Method for preparing LH / RH antagonistic peptide
EP0103077B1 (en) Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions
ATE52777T1 (en) SELECTIVE ALPHA ADRENEGIC RECEPTOR ANTAGONISTS.
DE69322613D1 (en) METHOD FOR PRODUCING CARBON TAR PECH SUITABLE FOR IMPREGNATING CARBON ELECTRODES
RU2205825C2 (en) Derivatives of thioamides, method for their preparing and pharmaceutical composition based on thereof
KR840005709A (en) Method for preparing a substituted peptide compound
KOMIYA et al. The Long-Term Effects of a Single Injection of β, β′-Immiodipropionitrile on Slow Axonal Transport in the Rat
Csapó et al. Peculiar myofilament changes near the intercalated disc in isoproterenol-induced cardiac muscle cell injury
Spencer et al. Pseudosarcoma of the pharynx and larynx
DE69934712D1 (en) METHOD OF PREPARING N-NEOHEXYL- (A) -ASPARTYL-L-PHENYL ALANINE METHYL ESTERS FROM INTERMEDIATE COMPOUNDS CONTAINING IMIDAZOLIDIN-4-ON
Ernst et al. Ameloblastoma in a female Wistar rat
Kroiher et al. Necessity of protein synthesis for metamorphosis in the marine hydroid Hydractinia echinata
KR960701088A (en) Phosphonomethyldipeptides

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950329

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee